Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EPS (Weighted Average and Diluted) (2016 - 2025)

Rockwell Medical (RMTI) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$0.05 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 225.0% year-over-year to -$0.05, compared with a TTM value of -$0.18 through Sep 2025, down 200.0%, and an annual FY2024 reading of -$0.03, up 91.89% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.05 for Q3 2025 at Rockwell Medical, roughly flat from -$0.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.04 in Q3 2024 and bottomed at -$1.04 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.28, with a median of -$0.07 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 1055.56% in 2021, then soared 157.14% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.04 in 2021, then soared by 95.19% to -$0.05 in 2022, then increased by 0.0% to -$0.05 in 2023, then rose by 20.0% to -$0.04 in 2024, then decreased by 25.0% to -$0.05 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RMTI at -$0.05 in Q3 2025, -$0.05 in Q2 2025, and -$0.04 in Q1 2025.